Delivery of therapeutic agents to a target site
AssigneeChesebrough-Pond's USA Co., Division of Conopco, Inc.
InventorsThomas S. Beggs, Paul J. Davis, Martine E. Verhoeyen
Life of this patent
Estimating the term…
Abstract
An antibody fragment able to bind to a target site is prolonged by an additional peptide. The Therapeutic agent is bound to this peptide or means are provided to bring about such binding. The antibody fragment and possibly also the therapeutic agent are included in a product so that binding to the target site delivers the therapeutic agent to the vicinity. The product may for example be for dental care, such as a toothpaste or mouthwash and the antibody fragment may then bind to a component of dental plaque.
Claims10
A product for treating a human body target site, which site is located in the human mouth and is accessible by topical application, with a therapeutic agent, said product being selected from the group consisting of mouthwash, toothpaste, and lozenge, said product comprising:
- (a) a therapeutic agent;
- (b) a first antibody formed from at least one peptide chain and which is able to bind to the target site through antibody-antigen binding, said first antibody fragment having a first additional peptide other than a fragment of the same antibody, appended thereto through a covalent peptide bond;
- and
- (c) a second antibody fragment able to bind through antibody-antigen binding to said first additional peptide and to bind the therapeutic agent to said first additional peptide, whereby in use of the product binding of the first antibody fragment to the target site holds the therapeutic agent on the target site, for the therapeutic agent to act on the target site.
A method of delivering a therapeutic agent to a human body target site which site is located in the human mouth and is accessible by topical application which method comprises applying a product comprising
- (a) a therapeutic agent;
- (b) a first antibody fragment formed from at least one peptide chain and having a first additional peptide other than a fragment of the same antibody appended thereto by a covalent peptide bond so that the peptide chain of the antibody fragment is prolonged and terminated by said first additional peptide, and
- (c) a second antibody fragment able to bind through antibody-antigen binding to said first additional peptide, said second antibody fragment serving to link the therapeutic agent to said first additional peptide whereby the binding of the first antibody fragment to the target site holds the therapeutic agent on the target site, for the therapeutic agent to act on the target site.
A product for treating a human body target site, which site is located in the human mouth and is accessible by topical application, with a therapeutic agent, the product being selected from the group consisting of mouthwash, toothpaste, and lozenge, said product comprising:
- (a) a therapeutic agent:
- (b) a first antibody fragment formed from at least one peptide chain and which is able to bind to the target site, said antibody having at least a first additional peptide other than a fragment of the same antibody appended thereto through a covalent peptide bond so that the peptide chain of said first antibody fragment is prolonged and terminated by said first additional peptide, and
- (c) a second antibody fragment able to bind to said additional peptide and to said therapeutic agent.
A product according to claim 14 wherein said first additional peptide comprises a plurality of repeats of a shorter peptide.
Dependencies are inferred from the claim text.